MedAvanteProPhase

WCG MedAvante-ProPhase, located in Mercerville, New Jersey, is a leading provider of technology-enabled signal detection solutions for clinical trials focused on central nervous system disorders. This privately held company employs 138 people and generates annual revenue of $100 million. MedAvante-ProPhase specializes in improving clinician-reported diagnostic and outcome measurements by standardizing rating scale administration and scoring. Their Virgil® Investigative Study Platform empowers site raters with tablet computers featuring context-sensitive electronic rating scale forms and study-specific clinical guidance, designed for clinicians, by clinicians. They offer comprehensive clinical rater training, ensuring quality data through independent review and oversight by expert central clinicians. A unique feature of MedAvante-ProPhase is the Independent Ratings service. This offering goes beyond standardized administration and scoring, mitigating perception bias that can hinder signal detection. Their independent, remote Expert Clinicians remain blind to protocol details and subject history, avoiding the influence of repeated patient contact and enrollment pressure. For further inquiries, please contact MedAvante-ProPhase via their website: www.medavante.com.